Tev-Tropin (JR-401S) / JCR Pharma, Teva - LARVOL DELTA

The ZOMATRIP study: 4 Year combination therapy of GH and GnRHa in girls with a short predicted adult height during early puberty: Interim results at the end of the treatment phase (ESPE 2014) - Abstract #; P4, N=24; Study ID: ZOMATRIP (NCT00840944); "A 4-year combination treatment of GH and triptorelin was safe and significantly increased height (7.2 cm or 1.2 SDS) above the predicted adult height after the treatment phase. The participants will be followed until final height to determine the full growth promoting effect of this intervention in comparison to historic matched untreated controls."

P4 data • Growth Hormone

Surveillance of treatment of children with growth hormone deficiency with Zomacton (clinicaltrials.gov) - P=Obs, N=0; Sponsor: Ferring Pharmaceuticals; N=200->0; Not yet recruiting -> Withdrawn (Change of local requirements).

Trial withdrawal • Growth Hormone

Human Growth Hormone Pre-treatment for 6 Weeks Prior to Ovulation Induction for IVF (clinicaltrials.gov) - P1/2; N=30; Not yet recruiting; Sponsor: Center for Human Reproduction

New P1/2 trial • Biosimilar • Growth Hormone • Oncology

Early hGH Treatment of SGA Infants to Prevent Irreversible Neurologic and Psychological Damage and Sequelae (clinicaltrials.gov) - P2; N=20; Not yet recruiting; Sponsor: Tel-Aviv Sourasky Medical Center

New P2 trial • Biosimilar • Growth Hormone

ADHERENCE TO TREATMENT WITH ZOMAJET, A NEEDLE- FREE DEVICE TRANSJECTING GROWTH HORMONE: RESULTS OF A FRENCH OBSERVATIONAL SURVEY (ESPE 2017) - "This study evaluated pediatric compliance with somatropin (Zomacton™) delivered via ZomaJet needle -free devices (ZomaJet Vision X or ZomaJet 2 Vision). Subjects receiving somatropin administered via ZomaJet needle-free devices had high compliance rates and good clinical outcomes, despite some reports of poor tolerability and ISRs."

Biosimilar • Growth Hormone • Ophthalmology • Pain

RAZANT: Study to Assess Long-term Effectiveness of Zomacton® and Treatment Adherence in Patients With Growth Hormone Deficiency or Ullrich-Turner Syndrome (clinicaltrials.gov) - P=N/A; N=700; Not yet recruiting; Sponsor: Ferring Pharmaceuticals; Initiation date: Feb 2018 ➔ Mar 2018

Trial initiation date • Biosimilar • Growth Hormone

Evaluation of the adherence and the patient acceptability of Zomacton treatment with the zomajet vision X device (ZOMAXEPT) (clinicaltrials.gov) - P=Obs, N=90; Sponsor: Ferring Pharmaceuticals; Not yet recruiting; Primary completion date: Mar 2014 -> Jun 2014.

Trial primary completion date • Growth Hormone